Related references
Note: Only part of the references are listed.A Tri-Marker Proliferation Index Predicts Biochemical Recurrence after Surgery for Prostate Cancer
Sameer Malhotra et al.
PLOS ONE (2011)
Impact of the primary Gleason pattern on biochemical recurrence-free survival after radical prostatectomy: a single-center cohort of 1,248 patients with Gleason 7 tumors
Olivier Alenda et al.
WORLD JOURNAL OF UROLOGY (2011)
Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer
Shi Yan et al.
BMC CANCER (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
The Ability of Biomarkers to Predict Systemic Progression in Men with High-Risk Prostate Cancer Treated Surgically Is Dependent on ERG Status
R. Jeffrey Karnes et al.
CANCER RESEARCH (2010)
Topoisomerase IIα expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer
Christian Schindlbeck et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy
Nicolas Tsavaris et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer
Karim Fizazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Topoisomerase II α Status in Renal Medullary Carcinoma: Immuno-Expression and Gene Copy Alterations of a Potential Target of Therapy
Roula Albadine et al.
JOURNAL OF UROLOGY (2009)
Topoisomerase IIα mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis
Areeg Faggad et al.
MODERN PATHOLOGY (2009)
Expression of Human DNA Topoisomerase II-α in Squamous Cell Carcinoma of the Larynx and Its Correlation With Clinicopathologic Variables
Jacob Shvero et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
The significance of Epstein Barr Virus (EBV) & DNA Topoisomerase II alpha (DNA-Topo II alpha) immunoreactivity in normal oral mucosa, Oral Epithelial Dysplasia (OED) and Oral Squamous Cell Carcinoma (OSCC)
Ali A. Shamaa et al.
DIAGNOSTIC PATHOLOGY (2008)
Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival
Amanda J. Murphy et al.
CANCER RESEARCH (2007)
Topoisomerase IIα gene amplification in gastric carcinomas:: correlation with the HER2 gene.: An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study
Sammy Yasmin Kanta et al.
HUMAN PATHOLOGY (2006)
Topoisomerase IIα expression correlates with diminished disease-free survival in invasive breast cancer
John K. O'Connor et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Topoisomerase II-α expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma
C. Hughes et al.
JOURNAL OF CLINICAL PATHOLOGY (2006)
Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples
RE Mueller et al.
GENES CHROMOSOMES & CANCER (2004)
Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma
U Vaishampayan et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2004)
Identification of functional nuclear export sequences in human topoisomerase IIα and β
SEL Mirski et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
High expression of DNA topoisomerase IIα and Ki-67 antigen is associated with prolonged survival glioblastoma patients
M Bredel et al.
EUROPEAN JOURNAL OF CANCER (2002)
Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer
WH Gotlieb et al.
GYNECOLOGIC ONCOLOGY (2001)
Predictive value of topoisomerase IIα immunostaining in urothelial bladder carcinoma
L Nakopoulou et al.
JOURNAL OF CLINICAL PATHOLOGY (2001)
Share Paper
